About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Press Releases 2018
Biocon Biologics
/
News – Posts
/
Press Releases
/
Press Releases 2018
Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children’s Park to the Community
Sun, 02-Dec-2018
Posted by: Biocon Biologics
No Comments
Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018
Tue, 30-Oct-2018
Posted by: Biocon Biologics
No Comments
Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%
Thu, 25-Oct-2018
Posted by: Biocon Biologics
No Comments
Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
Fri, 19-Oct-2018
Posted by: Biocon Biologics
No Comments
Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
Fri, 21-Sep-2018
Posted by: Biocon Biologics
No Comments
Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr
Thu, 26-Jul-2018
Posted by: Biocon Biologics
No Comments
Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA
Thu, 28-Jun-2018
Posted by: Biocon Biologics
No Comments
U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
Tue, 05-Jun-2018
Posted by: Biocon Biologics
No Comments
Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018
Mon, 04-Jun-2018
Posted by: Biocon Biologics
No Comments
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA
Sat, 02-Jun-2018
Posted by: Biocon Biologics
No Comments
1
2